Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172138
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIbánez, Mariam-
dc.contributor.authorCarbonell Caballero, José-
dc.contributor.authorSuch, Esperanza-
dc.contributor.authorGarcía Alonso, Luz-
dc.contributor.authorLiguori, Alessandro-
dc.contributor.authorLópez Pavía, María-
dc.contributor.authorLlop, Marta-
dc.contributor.authorAlonso, Carmen-
dc.contributor.authorBarragán, Eva-
dc.contributor.authorGómez Seguí, Inés-
dc.contributor.authorNeef, Alexander-
dc.contributor.authorHervás, David-
dc.contributor.authorMontesinos, Pau-
dc.contributor.authorSanz, Guillermo-
dc.contributor.authorSanz, Miguel Angel-
dc.contributor.authorDopazo, Joaquín-
dc.contributor.authorCervera, José-
dc.date.accessioned2020-11-17T13:23:06Z-
dc.date.available2020-11-17T13:23:06Z-
dc.date.issued2018-10-10-
dc.identifier.urihttp://hdl.handle.net/2445/172138-
dc.description.abstractAcute myeloid leukemia (AML) is associated with the sequential accumulation of acquired genetic alterations. Although at diagnosis cytogenetic alterations are frequent in AML, roughly 50% of patients present an apparently normal karyotype (NK), leading to a highly heterogeneous prognosis. Due to this significant heterogeneity, it has been suggested that different molecular mechanisms may trigger the disease with diverse prognostic implications. We performed whole-exome sequencing (WES) of tumor-normal matched samples of de novo AML-NK patients lacking mutations in NPM1, CEBPA or FLT3-ITD to identify new gene mutations with potential prognostic and therapeutic relevance to patients with AML. Novel candidate-genes, together with others previously described, were targeted resequenced in an independent cohort of 100 de novo AML patients classified in the cytogenetic intermediate-risk (IR) category. A mean of 4.89 mutations per sample were detected in 73 genes, 35 of which were mutated in more than one patient. After a network enrichment analysis, we defined a single in silico model and established a set of seed-genes that may trigger leukemogenesis in patients with normal karyotype. The high heterogeneity of gene mutations observed in AML patients suggested that a specific alteration could not be as essential as the interaction of deregulated pathways.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherPublic Library of Science (PLoS)-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0202926-
dc.relation.ispartofPLoS One, 2018, vol. 13, num. 10, p. e0202926-
dc.relation.urihttps://doi.org/10.1371/journal.pone.0202926-
dc.rightscc by (c) Ibáñez et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationLeucèmia mieloide-
dc.subject.classificationGenètica-
dc.subject.otherMyeloid leukemia-
dc.subject.otherGenetics-
dc.titleThe modular network structure of the mutational landscape of Acute Myeloid Leukemia-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2020-11-11T17:40:02Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid30303964-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
IbanezM.pdf4.71 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons